We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
It becomes necessary for pharmaceutical enterprises to make long-term strategic plans to deal with changes brought by policies upon China’s proposal of the Made in China 2025 strategy.